3488 completed. 3488 Phase 2, 754 Phase 1, 147 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3488 | Completed 3488 |
| Phase 1 | 754 | Completed 754 |
| Phase 3 | 147 | Completed 147 |
Follow Hematologic Diseases: new trials by email Literature Review of Hematologic Diseases trials Research Report on Hematologic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Omega 3 Fatty Acids on Heart and Liver in Beta Thalassemia Patients Omega 3 Fish Oil supplements, Deferasirox - Thalassemia Majors (Beta-Thalassemia Major) | Phase 2 | Completed | Ain Shams University | 100 | 2026-01-01 | 2026-10-07 |
| Effects of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, and Clinical Outcomes in Patients With Pneumonia and Sepsis Placebo Tablet(s), DLBS1033 - Pneumonia, Sepsis | Phase 2 | Completed | Universitas Sebelas Maret | 50 | 2025-08-14 | 2026-10-23 |
| A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure PN20, Placebo - Thrombocytopenia Associated With Chronic Liver Disease | Phase 1 / Phase 2 | Completed | Chongqing Peg-Bio Biopharm Co., Ltd. | 54 | 2025-06-06 | 2026-10-22 |
| A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) XH-S003 Capsule - PNH - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 26 | 2025-05-21 | 2026-11-18 |
| A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD) HBI-002 - Anemia, Sickle Cell | Phase 2 | Completed | Hillhurst Biopharmaceuticals, Inc. | 13 | 2025-02-15 | 2026-08-06 |
| Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2) zinc sulfate, Placebo - Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Indiana University | 100 | 2025-02-10 | 2026-01-30 |
| A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders Hem101 - Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL | Phase 1 / Phase 2 | Completed | National Research Center for Hematology, Russia | 58 | 2024-11-26 | 2026-02-09 |
| A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria(PNH) HSK39297 - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 47 | 2024-07-17 | 2025-06-29 |
| A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201) Foscenvivint - Liver Cirrhosis | Phase 2 | Completed | Kiminori Kimura, MD | 5 | 2024-05-08 | 2026-05-01 |
| Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP) Lusutrombopag Oral Tablet - Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia | Phase 2 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 17 | 2024-04-17 | 2025-12-19 |
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm CD123 targeted CAR-NK cells - Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Completed | Chongqing Precision Biotech Co., Ltd | 5 | 2024-03-28 | 2026-08-05 |
| Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic Syndrome Ustekinumab 90 mg - Behcet's Syndrome, Intestinal Type, Myelodysplastic Syndrome | Phase 2 | Completed | Liu Tian | 8 | 2024-03-24 | 2026-05-13 |
| Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor STSP-0601 for Injection - Hemophilia | Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 25 | 2024-03-18 | 2025-01-22 |
| Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease Etavopivat - Sickle Cell Disease | Phase 2 | Completed | Novo Nordisk A/S | 12 | 2024-03-09 | 2026-04-08 |
| Comparative Analysis of Oral Iron With Injectable Ferric Carboxymaltose for Post Partum Iron Deficiency Anaemia Ferric Carboxymaltose (FCM) - Anemia, Anemia, Postpartum | Phase 2 / Phase 3 | Completed | ESI-PGIMSR, Basaidarapur | 200 | 2024-03-01 | 2026-06-15 |
| Study of AZD9829 in CD123+ Hematological Malignancies AZD9829 - Hematological Malignancies | Phase 1 / Phase 2 | Completed | AstraZeneca | 56 | 2024-01-31 | 2026-07-01 |
| Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease Epeleuton - Sickle Cell Disease | Phase 2 | Completed | Afimmune | 35 | 2024-01-10 | 2026-05-04 |
| A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia HT-6184 - Myelodysplastic Syndrome, Anemia in Myelodysplastic Syndromes | Phase 2 | Completed | Halia Therapeutics, Inc. | 37 | 2023-12-09 | 2026-11-10 |
| AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma AD17002, Placebo - Eosinophilic Asthma | Phase 1 / Phase 2 | Completed | Advagene Biopharma Co. Ltd. | 40 | 2023-11-27 | 2025-09-10 |
| Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria HRS-5965 tablets - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 26 | 2023-11-15 | 2024-10-15 |
Showing 20 of 3488. Sign in to see all of them.
Multiple Myeloma (747) · Leukemia, Myeloid, Acute (698) · Leukemia (651) · Leukemia, Lymphocytic, Chronic, B-Cell (510) · Myelodysplastic Syndromes (494) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (452) · Lymphoma (311) · Lymphoma, Non-Hodgkin (295) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (228) · Lymphoma, Follicular (223) · Recurrence (199) · Hodgkin Disease (198) · Lymphoma, Mantle-Cell (196) · Lymphoma, B-Cell, Marginal Zone (193) · Neoplasms, Plasma Cell (193)
Hemic and Lymphatic Diseases (3488) · Neoplasms (2462) · Neoplasms by Histologic Type (2378) · Immune System Diseases (1849) · Immunoproliferative Disorders (1648) · Lymphoproliferative Disorders (1622) · Pathological Conditions, Signs and Symptoms (1235) · Pathologic Processes (1198) · Lymphatic Diseases (1083) · Leukemia (1057) · Hemorrhagic Disorders (1049) · Disease Attributes (1047) · Bone Marrow Diseases (999) · Leukemia, Myeloid (927)
Cyclophosphamide (406) · Dexamethasone (299) · Cytarabine (242) · fludarabine phosphate (222) · Lenalidomide (202) · Rituximab (190) · Filgrastim (188) · Melphalan (170) · Bortezomib (162) · Busulfan (157) · Peripheral Blood Stem Cell Transplantation (156) · fludarabine (156) · Methotrexate (147) · Cyclosporine (127) · Mycophenolic Acid (127)
M.D. Anderson Cancer Center (215) · National Cancer Institute (NCI) (140) · Fred Hutchinson Cancer Center (117) · Novartis Pharmaceuticals (83) · Memorial Sloan Kettering Cancer Center (79) · Mayo Clinic (65) · National Heart, Lung, and Blood Institute (NHLBI) (60) · Amgen (48) · Celgene (43) · Dana-Farber Cancer Institute (43) · H. Lee Moffitt Cancer Center and Research Institute (37) · GlaxoSmithKline (33) · Bristol-Myers Squibb (32) · Masonic Cancer Center, University of Minnesota (31) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (31)
United States (2310) · Germany (329) · France (315) · Italy (304) · Canada (299) · United Kingdom (265) · Spain (199) · Australia (141) · China (125) · Japan (111) · Netherlands (110) · Poland (110) · Belgium (103) · South Korea (101) · Austria (94)
Brenda Sandmaier (13) · Jorge Cortes, MD (12) · Guillermo Garcia-Manero, MD (10)
PMID 36005278, PMID 32499241, PMID 33783815, PMID 23524640, PMID 34724566, PMID 23065508, PMID 30957581, PMID 34515338, PMID 35622074, PMID 23738544, PMID 27209293, PMID 29358183, PMID 29674506, PMID 30062662, PMID 34175041, PMID 35549810, PMID 36184192, PMID 36240296, PMID 19216617, PMID 23620574, PMID 25361995, PMID 27658437, PMID 28835440, PMID 29958797, PMID 30885996, PMID 31171508, PMID 31221778, PMID 33242441, PMID 34922648, PMID 35235189, PMID 36791280, PMID 37934000, PMID 37975597, PMID 40156952, PMID 17715389, PMID 18596230, PMID 18997171, PMID 19005182, PMID 19667400, PMID 19846889, PMID 20661232, PMID 21403127, PMID 21527516, PMID 21623761, PMID 22067384, PMID 22133778, PMID 22430088, PMID 23547837, PMID 23886836, PMID 24383844
P30CA015704 (49), P30CA015083 (44), U10CA031946 (34), 2017 (29), 2016 (28), 2015 (27), 2008 (26), 2014 (25), 2009 (24), U10CA032102 (24), P30CA006973 (23), 2005 (22), 2018 (21), P30CA016672 (16), P01CA018029 (15)